BD Earnings Reports

BD delivered a strong performance in the fourth quarter of fiscal 2025, with significant growth in revenue and adjusted diluted EPS. The company's resilient business model and operational execution drove 3.9% organic growth in New BD, along with substantial adjusted margin and earnings expansion. Strategic initiatives, including the upcoming combination of Biosciences and Diagnostic Solutions with Waters Corporation, are on track to further enhance long-term value.

BD delivered a robust performance in the third quarter of fiscal 2025, with total revenues reaching $5.51 billion, marking a 10.4% increase year-over-year. Both GAAP and adjusted diluted EPS saw substantial growth, reaching $2.00 and $3.68 respectively. The company's operating income surged by 46.6%, reflecting strong operational efficiency and the positive impact of BD Excellence. BD also raised its full-year adjusted diluted EPS guidance, underscoring confidence in its continued financial performance.

BD (Becton, Dickinson and Company) delivered $5.27B in revenue and exceeded earnings expectations through margin expansion, even as organic growth remained soft in a challenging macro environment.

BD reported a strong operational performance in Q1 2025, with revenue growth, margin expansion, and earnings per share exceeding expectations. The company's revenue reached $5.2 billion, a 9.8% increase as reported and a 3.9% increase organically. Adjusted diluted EPS grew by 28.0% to $3.43. BD has also increased its FY25 adjusted diluted EPS guidance at the midpoint, while absorbing translational currency impacts.

BD reported Q4 revenue of $5.4 billion, a 6.9% increase as reported. GAAP EPS grew 173.6% to $1.45, and adjusted EPS grew 11.4% to $3.81. The company issued FY25 adjusted diluted EPS guidance of $14.25 to $14.60, reflecting growth of about 10% at the midpoint.

BD reported Q3 fiscal 2024 results with revenue of $5.0 billion and adjusted revenue of $5.1 billion. GAAP diluted EPS was $1.68 and adjusted diluted EPS was $3.50, representing growth of 23.5% and 18.2%, respectively. The company updated its fiscal 2024 GAAP revenue growth guidance to approximately 3.7%, and its organic revenue growth guidance to 5.0% to 5.25%. The company increased its fiscal 2024 adjusted diluted EPS guidance by 5 cents at the midpoint to $13.05 to $13.15.

BD reported Q2 2024 financial results with revenue of $5.0 billion, a 4.6% increase as reported. GAAP EPS grew by 20.9% to $1.85, and adjusted diluted EPS increased by 10.8% to $3.17. The company raised its full-year adjusted EPS guidance and affirmed its organic revenue growth guidance.

BD reported Q1 revenue of $4.7 billion, a 2.6% increase as reported and a 2.4% organic increase. GAAP EPS was $0.96 and adjusted EPS was $2.68. The company raised its full-year adjusted EPS guidance and midpoint of organic revenue growth guidance.

BD reported Q4 revenue of $5.1 billion, a 6.8% increase as reported and a 5.9% increase on a currency-neutral basis. GAAP EPS was $0.53 and adjusted diluted EPS was $3.42. The company issued FY24 guidance, including 5.75% organic revenue growth at the midpoint of the 5.25% to 6.25% range.

BD reported a revenue of $4.9 billion, a 5.1% increase as reported and 6.3% on a currency-neutral basis. The company raised its full-year base organic revenue growth guidance and maintained its full-year adjusted EPS guidance.

BD reported revenue of $4.8 billion, a 1.5% increase as reported and 4.1% on a currency-neutral basis. The company raised its full-year base revenue guidance, enabling additional investments in growth and innovation while absorbing lower COVID-only diagnostic testing revenue and incremental FX impacts.

BD reported a decrease in revenue of 2.8% as reported, but an increase of 1.7% on a currency-neutral basis. The company's base business revenue grew 0.4% as reported and 5.2% on a currency-neutral basis. GAAP EPS was $1.70 and adjusted EPS was $2.98. The company raised its full-year revenue and adjusted EPS guidance.

BD reported Q4 revenue of $4.761 billion, a decrease of 1.8% as reported, but an increase of 2.3% on a currency-neutral basis. The revenue performance was driven by a base revenue growth of 4.2% as reported, and 8.6% currency-neutral. GAAP diluted EPS was $0.92 and adjusted diluted EPS was $2.75. The company issued FY23 guidance and announced its 51st consecutive year of dividend increases, raising the dividend by 4.6%.

BD reported revenue from continuing operations of $4.6 billion, a 0.7% increase as reported and 3.8% on a currency-neutral basis. Base revenue growth was 6.0% as reported and 9.3% currency-neutral. GAAP diluted EPS from continuing operations was $1.28, while adjusted diluted EPS from continuing operations was $2.66. The company raised full year revenue and EPS guidance.

BD (Becton, Dickinson and Company) announced results for its second quarter of fiscal year 2022. Revenue of $5.0 billion increased 2.1% as reported and 3.9% on a currency-neutral basis. GAAP diluted EPS was $1.50 and adjusted diluted EPS was $3.18. The company raised the mid-point of its full-year revenue and adjusted EPS guidance ranges, adjusting for the completed spin of Diabetes Care business.

BD reported a 6.0% decrease in revenue to $5.0 billion, driven by a significant decline in COVID-19 testing revenues. However, the company saw an 8.1% increase in base revenues. The company reported GAAP EPS of $2.28 and adjusted EPS of $3.64. BD raised its full year revenue and EPS guidance, reflecting confidence in its BD2025 strategy and strong base business performance.

BD reported a 7.3% increase in revenue to $5.1 billion for the fourth fiscal quarter. GAAP EPS increased 133.3% to $0.84, while adjusted EPS decreased 7.2% to $2.59. The company issued fiscal year 2022 revenue guidance of $19.3 to $19.5 billion and adjusted diluted EPS guidance of $12.30 to $12.50.

BD (Becton, Dickinson and Company) reported strong third-quarter results with revenues of $4.9 billion, a 26.9% increase year-over-year on a reported basis. The growth was primarily driven by strong base business performance and increased healthcare utilization levels. The company raised its fiscal year 2021 revenue growth and adjusted EPS guidance ranges, citing base business momentum.

BD (Becton, Dickinson and Company) reported a 15.4% increase in quarterly revenues to $4.9 billion for the second fiscal quarter ended March 31, 2021. This growth was driven by COVID-19 diagnostic revenues of $480 million and strong core business growth. GAAP diluted EPS increased 77.4% year-over-year to $0.94, and adjusted EPS increased 25.1% year-over-year to $3.19. The company reaffirmed its fiscal 2021 revenue growth and adjusted EPS guidance.